Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Check out some of our latest original content that was created and distributed as part of our ongoing collaborations with IR firms and other companies.

MissionIRNewsBreaks – Newton Golf Company Inc. (NASDAQ: NWTG) Expands Performance-Driven Portfolio with ‘Fast Motion’

Newton Golf Company (NASDAQ: NWTG) is positioned for opportunity as it brings innovation to golf players seeking performance gains. The company recently launched its latest product: the Fast Motion shaft family, aiming to redefine performance standards and capitalize on the growing appetite for cutting-edge golf technology. “Newton Golf’s new Fast Motion shaft exemplifies how a company can use innovation to sharpen its competitive edge. This latest addition to the Newton shaft lineup introduces a lighter-weight, high-performance alternative to existing models. Designed for golfers seeking increased distance and higher swing speeds, the Fast Motion shaft delivers these enhancements without compromising control or accuracy. In doing so, Newton continues to build on its strong reputation for combining advanced engineering with a deep understanding of player needs.”

To view the full article, visit https://ibn.fm/vi3q3

About Newton Golf Company Inc.

Newton Golf harnesses the power of physics to revolutionize golf equipment design. Formerly known as Sacks Parente, the company’s rebranding reflects its commitment to innovation inspired by Sir Isaac Newton, the father of physics. By applying Newtonian principles to every aspect of its design process, Newton Golf creates precision-engineered golf clubs that deliver unmatched stability, control, and performance. The company’s mission is to empower golfers with scientifically advanced equipment that maximizes consistency and accuracy, ensuring every swing is backed by the laws of physics.

For more information, visit the company’s website at www.NewtonGolfIR.com.

NOTE TO INVESTORS: The latest news and updates relating to NWTG are available in the company’s newsroom at https://ibn.fm/NWTG

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in Newton Golf Comp. NWTG | Leave a comment

MissionIRNewsBreaks – FAVO Capital Inc. (FAVO) Poised in New Era for Tech-Enabled SMB Lending

As the private credit market continues to evolve, FAVO Capital (OTC: FAVO) is positioned to capitalize on emerging opportunities. “FAVO stands out as a leading private credit provider, specializing in delivering fast, efficient and personalized funding solutions to small and mid-sized businesses (‘SMBs’) across the United States and the Dominican Republic. Leveraging advanced technology and data-driven underwriting processes, FAVO Capital offers a range of financing options, including revenue-based funding and merchant cash advances, designed to accommodate the diverse financial requirements of SMBs,” reads a recent article. “The company’s recent initiatives, including a $8 million Series A preferred investment and plans to uplist to the Nasdaq, signal a strong trajectory of growth and institutional engagement. By staying at the forefront of industry trends and maintaining a client-centric approach, FAVO Capital exemplifies the transformative potential of private credit in empowering SMBs and driving economic progress.”

To view the full article, visit https://ibn.fm/qXaPA

About FAVO Capital Inc.

FAVO Capital is a rapidly growing alternative finance company headquartered in Fort Lauderdale, Florida. The company offers personalized alternative finance solutions to emerging, small and medium-sized businesses. “FAVO” is “Honeycomb” in Latin – The Honeycomb (Hexagon) is the most efficient shape in the universe. FAVO intends to be efficient, flexible and durable. For more information visit www.FAVOCapital.com.

NOTE TO INVESTORS: The latest news and updates relating to FAVO are available in the company’s newsroom at https://ibn.fm/FAVO

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in FAVO Capital Inc. FAVO | Leave a comment

MissionIRNewsBreaks – Why Solowin Holdings (NASDAQ: SWIN) Is ‘One to Watch’

Solowin Holdings (NASDAQ: SWIN) is focused on delivering comprehensive investment solutions from traditional finance as well as decentralized finance to high-net-worth and institutional clients. “Operating through its wholly owned subsidiary, Solomon JFZ (Asia) Holdings Limited, Solowin is licensed by the Hong Kong Securities and Futures Commission and offers access to a full suite of financial services through its secure, one-stop electronic platform, Solomon Win,” reads a recent article. “Driven by a vision to create a modernized financial services infrastructure, especially to bridging traditional finance and the Web3 technology, Solowin has prioritized innovation, agility, and client-first experiences. The firm has experienced robust growth, aligning itself with evolving capital markets and emerging technologies. Its investment strategy is designed to enable seamless access to capital markets and diversified investment opportunities through cutting-edge financial technology.”

To view the full article, visit https://ibn.fm/mTvIG

About Solowin Holdings

Solowin Holdings is a Hong Kong based financial services firm providing a comprehensive one-stop solution for high-net-worth and institutional investors worldwide. Spanning both traditional and virtual assets, Solowin’s offerings include investment banking, wealth management, asset management, and Web3 solutions, tailored to support the next generation of investors. Solowin’s wholly owned subsidiary, Solomon JFZ (Asia) Holdings Limited, is one of Hong Kong’s first regulated virtual asset service providers. Its advanced electronic platform, Solomon VA+, is Hong Kong’s first app to integrate traditional and virtual asset trading with wealth management services. For more information, visit the company’s website at https://solowin.io.

NOTE TO INVESTORS: The latest news and updates relating to SWIN are available in the company’s newsroom at https://ibn.fm/SWIN

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in Solowin Holdings. SWIN | Leave a comment

Soligenix Inc. (NASDAQ: SNGX) Highlights Encouraging Phase 3 Progress for HyBryte(TM) in Investment Webinar

  • A focus during the webinar was the investigator-initiated study currently being conducted at the University of Pennsylvania under the leadership of Dr. Ellen Kim.
  • Interim results show that among the first eight patients who completed 18 weeks of treatment, 75% demonstrated a greater than 50% reduction in disease severity.
  • Soligenix anticipates top-line results from the phase 3 trial in the second half of 2026.

In a recent webinar hosted by Allele Capital, Soligenix (NASDAQ: SNGX) executives Dr. Christopher Schaber and Dr. Christopher Pullion shared detailed updates on the company’s HyBryte(TM) (synthetic hypericin) clinical development (https://ibn.fm/dz7eO). The event offered an in-depth look at Soligenix’s ongoing confirmatory phase 3 trial for cutaneous T-cell lymphoma (“CTCL”), a rare non-Hodgkin’s lymphoma, and discussed promising data emerging from an investigator-initiated study conducted at the University of Pennsylvania. Soligenix, a late-stage biopharmaceutical company, is dedicated to developing and commercializing treatments for rare diseases and unmet medical needs, and HyBryte(TM) represents the company’s lead asset aimed at transforming the treatment landscape for CTCL.

HyBryte(TM) is a topical therapy activated by visible light that is applied directly to cancerous lesions on the skin, primarily targeting early-stage mycosis fungoides, which account for nearly 90% of CTCL cases. According to Dr. Schaber, Soligenix chairman, president and CEO, CTCL affects approximately 40,000 patients worldwide and is considered a chronic, relapsing disease that currently lacks an approved front-line treatment. HyBryte(TM) has the potential to fill that void, representing a significant commercial and therapeutic opportunity, with Soligenix estimating a market potential of more than $250 million globally and approximately $100 million in peak U.S. sales.

A central focus of the webinar was the investigator-initiated study currently being conducted at the University of Pennsylvania under the leadership of Dr. Ellen Kim, a recognized expert in CTCL and the lead principal investigator for both the original FLASH study and the ongoing phase 3 confirmatory FLASH2 trial. The study was designed to simulate real-world conditions by administering HyBryte(TM) twice weekly for up to one year, without treatment breaks, until patients reached disease clearance or a one-year mark. Using the Composite Assessment of Index Lesion Severity (“CAILS”) scoring system — a validated clinical tool and the gold standard in CTCL trials — researchers evaluated changes in lesion severity and response to treatment.

Interim results from the study were encouraging, reported Dr. Pullion, Soligenix medical director and CTCL program lead. Among the first eight patients who completed 18 weeks of treatment, 75% (six patients) demonstrated a greater than 50% reduction in disease severity, meeting the defined treatment response threshold. Moreover, 85% of patients across the study achieved similar reductions over time, and three patients reached complete remission with no visible lesions remaining. Importantly, the therapy exhibited an excellent safety profile with no serious adverse events, and participants showed strong compliance, further highlighting HyBryte(TM)’s potential as a well-tolerated, effective treatment for long-term disease management.

The findings from the study are particularly significant because of their close alignment with the ongoing phase 3 confirmatory FLASH2 trial. As Dr. Pullion explained, the phase 3 trial mirrors the treatment regimen used in the University of Pennsylvania study: the same dosage, the same scoring system and the same patient population. The primary endpoint in the phase 3 study is also measured at 18 weeks, the same time frame at which the earlier study showed strong results. Given the consistent methodology and encouraging parallels, Dr. Pullion expressed cautious optimism that the phase 3 trial will replicate the positive outcomes of earlier clinical trials and the investigator-initiated study.

Further comparisons between the clinical trials were outlined during the webinar. The original FLASH trial was the largest multicenter, double-blind, placebo-controlled study conducted for CTCL, and it met its primary endpoint of lesion improvement after treatment cycles that included treatment pauses. In contrast, the confirmatory phase 3 FLASH2 trial is designed to provide continuous therapy without breaks or pauses, which is expected to enhance efficacy, based on lessons learned from earlier trials. The current trial also benefits from participation by leading centers of excellence who are familiar with the therapy and motivated by the pressing need for new CTCL treatments.

Dr. Pullion emphasized that HyBryte(TM)’s ability to treat both patch and plaque lesions, often challenging for other topical therapies, is a major differentiator. Unlike some existing chemotherapeutic topical treatments that cause skin irritation or systemic side effects, HyBryte(TM) has shown minimal systemic absorption and a benign side effect profile. This positions it as a particularly attractive first-line option for CTCL patients, who often face lifelong treatment regimens and need therapies that are not only effective but also safe and tolerable over time.

As for what’s next, Schaber shared that Soligenix anticipates top-line results from the phase 3 FLASH2 trial in the second half of 2026. Meanwhile, an update on enrollment progress is expected later in 2025, with current trends suggesting enrollment is on track and may even be ahead of initial expectations. With data from the initial FLASH trial already published in JAMA Dermatology and the investigator-initiated study reinforcing the positive results, the company is entering a pivotal stage in development.

The webinar closed with both SNGX executives reiterating their commitment to addressing the critical unmet needs in CTCL. By building upon over a decade of research, clinical engagement and patient advocacy, Soligenix is positioning HyBryte(TM) not just as a novel therapeutic agent, but as a potential paradigm-shifting front-line treatment in the CTCL landscape.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in Soligenix Inc. SNGX | Leave a comment

Silvercorp Metals Inc. (NYSE-A: SVM) (TSX: SVM) Updated Resource Estimate for Condor Project Highlights High-Grade Underground Potential

  • Total indicated underground mineral resources of 3.17 million tonnes at Camp and Los Cuyes deposits, containing 0.37 million gold equivalent ounces at a cutoff grade of 2.2 g/t AuEq.
  • Total inferred underground mineral resources of 12.1 Mt at Camp and Los Cuyes deposits, containing 1.50 million gold equivalent ounces at a cutoff grade of 2.2 g/t AuEq. Ongoing 3,500-metre drill program set to expand known mineralization zones.
  • Preliminary Economic Assessment for underground operation expected by year-end 2025.
  • El Domo Project development on track with detailed cost breakdown and construction timeline targeting 2026 production.

Silvercorp Metals (NYSE-A: SVM) (TSX: SVM), a Canadian mining company producing silver, gold, lead, and zinc with a long history of profitability, has announced an updated mineral resource estimate (“MRE”) for its Condor Project, located in Ecuador’s Zamora-Chinchipe Province.

The new estimate, effective as of Feb. 28, 2025, was prepared by SRK Consulting (Canada) Inc., in accordance with National Instrument 43-101 standards, and marks the first step in Silvercorp’s effort to reposition Condor as a high-grade underground gold project (https://ibn.fm/J4HYK). An updated Preliminary Economic Assessment (“PEA”) is expected later this year. The project was previously envisioned as a low-grade, bulk-tonnage open pit, which would have been costly to develop and challenging to permit.

The update centers on the Camp and Los Cuyes deposits. At a cut-off grade of 2.2 g/t AuEq, indicated resources included 3.17 million tonnes at an average grade of 3.58 g/t AuEq, totaling 0.37 million ounces. Additionally, inferred resources included 12.1 million tonnes grading 3.84 g/t AuEq, totalling 1.50 million ounces AuEq.

Metallurgical testing yielded favorable gold recoveries: up to 96% at Camp and 88% at Los Cuyes based on cyanide leaching.

Although the underground strategy dominates the current outlook, Silvercorp also reported open-pit constrained resources at the Soledad and Enma deposits. These include 0.15 million ounces AuEq in the indicated category and 0.38 million in the inferred category, at cut-off grades of 0.5 g/t for Soledad and 0.6 g/t for Enma.

The Condor Project is located in a volcanic complex that intrudes older granodiorite rocks, where gold and silver mineralization is consistent with a low to intermediate sulphidation epithermal system. Mineralization styles vary across the deposits, including sub-vertical sulfide-bearing veins and wider zones of disseminated mineralization.

Gold is primarily associated with pyrite and sphalerite, with smaller amounts of galena and chalcopyrite. These characteristics shape the company’s ongoing exploration targets and development scenarios.

To advance the project, Silvercorp has launched a 3,500-metre (10 holes) surface drilling campaign in May 2025, testing areas where the company sees exploration potential. Drilling will focus on:

  • Broad zones of sub-horizontal disseminated gold mineralization in rhyolitic tuffs at Los Cuyes.
  • Contact zones between rhyolite domes and batholith granodiorite at Camp for wide mineralization.
  • Gap areas between Camp, Soledad, Los Cuyes, and Enma deposits, testing for potential connection and strike extension of mineralized structures.

In parallel, Silvercorp is advancing a PEA for an underground operation at Condor, expected by the end of 2025. The company is also working to secure the permits and community agreements required to develop underground exploration tunnels which it is planning to build in 2H 2026.

The Condor update follows Silvercorp’s recent construction budget announcement for the El Domo Project, also in Ecuador. The company expects to bring El Domo into production by the end of 2026 at a revised cost of $240.5 million, below the 2021 feasibility estimate of $247.6 million (https://ibn.fm/bd01V).

The development has been divided into several stages, each with its own budget and timeline:

  • Package #1: Site Preparation and Infrastructure – $47.5 million: Earthworks began earlier this year, with full site readiness targeted by Q4 2025.
  • Package #2: Open Pit Mining and Stripping – $39 million: This stage will begin in August 2025. It involves producing 43,000 tonnes of ore by end-2026 and creating a ready-to-mine inventory of 550,000 cubic metres of ore to support three years of production.
  • Package #3: Processing Plant and Equipment – $33 million: Engineering and equipment selection is being led by China’s Jinpeng Group, with construction slated to begin in September 2025.

Additionally, Silvercorp has signed a power line agreement with Ecuador’s state utility CNEL EP. Construction is set to begin in the summer of 2025, with an estimated completion time of 13–17 months. Final costs and contractor selections are still pending. In response to Ecuador’s seasonal power supply instability, Silvercorp has sourced diesel power generators to provide backup electricity. These will be operational before the process plant comes online.

Silvercorp’s ongoing investment in Ecuador reflects its long-term strategy to generate shareholder value through high-quality assets, free cash flow from established operations, and disciplined project development. With a portfolio that includes multiple projects in Ecuador and China, the company has an 18-year track record of profitability and remains focused on ensuring organic growth through extensive drilling for discovery; ongoing merger and acquisition efforts; and an unwavering commitment to responsible mining and ESG.

For more information, visit the company’s website at www.silvercorpmetals.com/welcome.

Third-Party Content Disclaimer

The IBN website may contain third-party content articles and other content submitted by third parties, including articles submitted through the IBN Premium Partnership Program. All opinions, statements and representations expressed by such third parties are theirs alone and do not express or represent the views and opinions of IBN or its affiliates and owners. Content created by third parties is the sole responsibility of such third parties, and IBN does not endorse, guarantee or make representations concerning the accuracy and completeness of any third-party content. You acknowledge that by IBN providing you with this internet portal that makes accessible to you the ability to view third party content through the IBN site, IBN does not undertake any obligation to you as a reader of such content or assume any liability relating to such third-party content. IBN expressly disclaims liability relating to such third-party content. IBN and its members, affiliates, successors, assigns, officers, directors, and partners assume no responsibility or liability that may arise from the third-party content, including, but not limited to, responsibility or liability for claims for defamation, libel, slander, infringement, invasion of privacy and publicity rights, fraud, or misrepresentation, or an private right of action under the federal securities laws of the United States or common law. Notwithstanding the foregoing, IBN reserves the right to remove third-party content at any time in its sole discretion. By viewing this third-party content, you acknowledge that you have viewed, read fully, accepted and agreed to all terms of the Disclaimer at https://IBN.fm/Disclaimer.

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in Silvercorp Metals Inc. SVM | Leave a comment

MissionIRNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Added to Four Russell Indexes in 2025 Reconstitution

Nutriband (NASDAQ: NTRB) has been added to the Russell Microcap, Russell Microcap Growth, Russell 3000E, and Russell 3000E Growth Indexes as part of the 2025 Russell indexes reconstitution. CEO Gareth Sheridan called the inclusion a reflection of market recognition and momentum behind the company’s AVERSA pipeline, particularly AVERSA Fentanyl, which has potential peak annual U.S. sales between $80 million and $200 million. Russell indexes, maintained by FTSE Russell, benchmark approximately $10.6 trillion in assets and are widely used by investment managers and institutions.

To view the full report, visit https://ibn.fm/Vcsgx

About Nutriband Inc.

Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its lead product under development is an abuse-deterrent fentanyl patch incorporating its AVERSA(TM) abuse-deterrent technology. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. For more information about the company, visit www.Nutriband.com.

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in Nutriband Inc. NTRB | Leave a comment

MissionIRNewsBreaks – Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM) Amends Payment Schedule for Iska Iska Interest, Updates Adjacent Property Agreement

Eloro Resources (TSX: ELO) (OTCQX: ELRRF) (FSE: P2QM) has reached a mutual agreement with Empresa Minera Villegas S.R.L. to amend the payment terms for acquiring 100% interest in the Iska Iska silver-tin polymetallic project in southern Bolivia. Of the remaining US$4.45 million owed, US$1.8 million in exploration spending on the adjacent Mina Casiterita property will be credited, with cash payments of US$1 million due July 15, 2025, and US$1.65 million due January 6, 2026. The related Mina Casiterita and Mina Hoyada option agreement has also been revised, calling for a US$1.8 million payment within 12 months of securing mining rights and issuance of 200,000 Eloro shares upon property transfer.

To view the full press release, visit https://ibn.fm/gKRN8

About Eloro Resources Ltd.

Eloro is an exploration and mine-development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec. Eloro has an option to acquire a 100% interest in the highly prospective Iska Iska Property, which can be classified as a polymetallic epithermal-porphyry complex, a significant mineral deposit type in the Potosi Department in southern Bolivia. A recent NI 43-101 technical report on Iska Iska, which was completed by Micon International Limited, is available on Eloro’s website and under its filings on SEDAR. Iska Iska is a road-accessible, royalty-free property. Eloro also owns an 82% interest in the La Victoria Gold/Silver Project, located in the north-central mineral belt of Peru, some 50 kilometers south of the Lagunas Norte Gold Mine and the La Arena Gold Mine. For more information about the company, visit www.EloroResources.com.

NOTE TO INVESTORS: The latest news and updates relating to ELRRF are available in the company’s newsroom at https://ibn.fm/ELRRF

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in Eloro Resources Ltd. ELRRF | Leave a comment

MissionIRNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Advancing Novel Immunotherapy to Combat Antibiotic Resistance

Soligenix (NASDAQ: SNGX) is at the forefront of the effort as the medical community urgently seeks alternative treatments for bacterial infections in the face of escalating antibiotic resistance. The company’s SGX943 therapy “is based on dusquetide, an Innate Defense Regulator (‘IDR’) that modulates the body’s immune response rather than directly targeting bacteria. By enhancing the innate immune system, SGX943 promotes the clearance of infections and reduces inflammation, offering a broad-spectrum approach to bacterial infections,” reads a recent article. “The company’s portfolio encompasses both specialized biotherapeutics and public health solutions, targeting areas with significant unmet medical needs.”

To view the full article, visit https://ibn.fm/FzyHN

About Soligenix Inc.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte(TM) (“SGX301” or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (“CTCL”). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (“SGX302”) into psoriasis, the company’s first-in-class innate defense regulator (“IDR”) technology, dusquetide (“SGX942”) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (“SGX945”) in Behçet’s disease.

The company’s Public Health Solutions business segment includes development programs for RiVax(R), its ricin toxin vaccine candidate, as well as its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax(TM), the company’s vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of Soligenix’s vaccine programs incorporates the use of its proprietary heat stabilization platform technology, known as ThermoVax(R). To date, this business segment has been supported with government grants and contract funding from the National Institute of Allergy and Infectious Diseases (“NIAID”), the Defense Threat Reduction Agency (“DTRA”) and the Biomedical Advanced Research and Development Authority (“BARDA”).

For further information, visit the company’s website at www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in Soligenix Inc. SNGX | Leave a comment

MissionIRNewsBreaks – Why Lantern Pharma Inc. (NASDAQ: LTRN) Is ‘One to Watch’

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company, is leveraging artificial intelligence and machine learning to redefine oncology drug development. Through its proprietary platform, RADR(R) (Response Algorithm for Drug Positioning & Rescue), Lantern is advancing a pipeline of precision cancer therapies. “Lantern Pharma’s AI-driven RADR(R) platform integrates over 200 billion oncology-specific data points and underpins every stage of its precision oncology pipeline,” reads a recent article. “The company has three lead drug candidates in clinical development, targeting major oncology markets including non-small cell lung cancer (‘NSCLC’), triple-negative breast cancer (‘TNBC’), and non-Hodgkin’s lymphoma (‘NHL’)… Starlight Therapeutics extends Lantern’s footprint into brain and CNS cancers, including pediatric indications supported by orphan and rare disease designations… Lantern has received multiple FDA designations including Fast Track, Orphan Drug, and Rare Pediatric Disease status across its portfolio, enhancing regulatory pathways.”

To view the full article, visit https://ibn.fm/4rjED

About Lantern Pharma Inc.
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. The company’s proprietary AI and machine learning platform, RADR(R), leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, Lantern has accelerated the development of its growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers. On average, Lantern’s newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $2.5 million per program.

NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in Lantern Pharma Inc. LTRN | Leave a comment

MissionIRNewsBreaks – Clene Inc. (NASDAQ: CLNN) Advances Regulatory Strategy for CNM-Au8 with FDA Meetings Scheduled for ALS and MS Programs

Clene (NASDAQ: CLNN) announced key regulatory developments following a Type C meeting with the FDA, where it received feedback on its statistical analysis plan (SAP) for evaluating neurofilament light (NfL) biomarker data from its Expanded Access Protocol for ALS. The company has resubmitted a revised SAP and anticipates FDA acceptance this summer, with NfL analyses scheduled for early Q4 2025 to support a potential NDA submission under the accelerated approval pathway. Clene also confirmed two additional FDA meetings in Q3 2025: one to assess long-term ALS survival data for accelerated approval consideration and another End-of-Phase 2 Type B meeting to review Phase 2 MS trial results and discuss a Phase 3 study targeting cognitive improvement.

To view the full press release, visit https://ibn.fm/lU5qu

About Clene Inc.

Clene (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in Clene Inc. CLNN | Leave a comment